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Abstract:  Silibinin,  an  effective  anti-cancer  and  chemopreventive  agent  in  various 
epithelial cancer models, has been reported to inhibit cancer cell growth through mitogenic 
signaling pathways. However, whether it can inhibit human pancreatic carcinoma growth 
and what are the underlying mechanisms is still not well elucidated. Here, we evaluated the 
inhibitory proliferation effects of Silibinin in pancreatic carcinoma growth and examined 
whether Silibinin modulates cell cycle and apoptosis. Our results indicate that Silibinin 
effectively  inhibited  the  pancreatic  carcinoma  AsPC-1,  BxPC-3  and  Panc-1  cells’ 
proliferation and caused apoptosis. Silibinin induced a decrease in S phase and cell cycle 
arrest in G1 phase in AsPC-1 cells, but had no obvious changes in BxPC-3 and Panc-1 cell 
cycle.  Furthermore,  these  results  suggest  that  Silibinin  might  be  a  candidate 
chemopreventive agent for pancreatic carcinoma therapy. 
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1. Introduction  
Silibinin is a major active constituent of silymarin, a mixture of flavonolignans extracted from milk 
thistle (Silybum marianum) [1]. Milk thistle extract has centuries-old history of use in folk medicine to 
treat a variety of illnesses including jaundice, gallstones, hemorrhage, bronchitis, varicose vein, and for 
several other purposes [2]. Silibinin is well tolerated and largely free of any adverse effects. Silibinin is 
nontoxic  in  acute,  subchronic  and  chronic  tests even  at  large  doses,  and  there  is  no  known  LD50  
for Silibinin in animal studies [3–6]. The anticancer efficacy of Silibinin is clearly evident from the 
published reports against various cancers including prostate, skin, lung, colon, breast, hepatic, ovarian, 
cervical, kidney, gastric carcinoma [2], and the underlying mechanisms are very different in different 
cancer cells. For instance, Silibinin activates p53 and induces autophagic death in human fibrosarcoma 
HT1080 cells via reactive oxygen species-p38 and c-Jun N-terminal kinase pathways [1]. Silibinin 
induces apoptosis by down-regulating survivin through inhibition of hypoxia-inducible factor-1 alpha 
in  non-small  cell  lung  cancer  cells  [7].  Silibinin  activates  p53-caspase  2  pathways  and  causes  
caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma 
RT4 cells [8]. Silibinin up-regulates the expression of cyclin-dependent kinase inhibitors and causes 
cell cycle arrest and apoptosis independent of caspases activation in human colon carcinoma HT-29 
cells [9]. 
Pancreatic cancer is a malignant neoplasm of the pancreas. It is estimated that in 2010 more than 
43,000 individuals in the United States have been diagnosed with this condition, and 36,800 have died 
from  this  disease  [10].  The  oncogenesis  of  pancreatic  cancer  in  particular  appears  to  favor  the 
development  and  subsequent  expansion  of  cell  clones  that  are  resistant to  apoptotic  triggers  [11]. 
Therefore, an important research objective is the identification of lead compounds that circumvent the 
resistance mechanisms that limit the success of conventional drugs. Anticancer activities of Silibinin in 
pancreatic cancer have not been examined and the underlying mechanism has not been clarified yet.  
The  purpose of  this  work  was to  develop  an  understanding  of  Silibinin’s  effects  on  pancreatic 
cancer cells to begin to determine its therapeutic value in preventing or treating this disease. Therefore 
we examined the anticancer activities of Silibinin, and investigated its mechanism in three pancreatic 
cancer cell  lines, AsPC-1, BxPC-3 and Panc-1. Silibinin  activated caspase 3,  8, 9 and caused cell 
apoptosis. Silibinin induced a decrease in S phase and cell cycle arrest in G1 phase in AsPC-1 cells, 
but resulted in no obvious changes in BxPC-3 and Panc-1 cell cycles. 
2. Results and Discussion 
2.1. Effect of Silibinin on AsPC-1, Panc-1 and BxPC-3 Cell Growth Inhibition 
To  examine  the  effects  of  Silibinin  on  AsPC-1,  Panc-1  and  BxPC-3  cancer  cell  growth,  we 
conducted a dose escalation experiment (Figure 1). The results indicate that Silibinin inhibited the 
proliferation of AsPC-1, Panc-1 and BxPC-3 cells in a dose- and time-dependent manner. Dimethyl 
sulfoxide (DMSO) is primarily used as a solvent for pharmaceutics and as a cryopreservant of cell 
lines. In this text, no differences were found between 2‰ (v/v) DMSO and the negative control. There 
was  a  significant  decrease  in  cell  proliferation  in  Panc-1  and  Bxpc-1  cells  observed  after  48  h 
treatment with 200 μM Silibinin. However, for AsPC-1 cells, there was a significant decrease in cell Int. J. Mol. Sci. 2011, 12 
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proliferation at a concentration of 100 μM Silibinin. That is, different cancer cells, even if coming 
from the same tissue, have different sensitivities to Silibinin. 
Figure 1. Silibinin inhibits proliferation of AsPC-1 (A), Panc-1 (B) and BxPC-3 (C) cells. 
Cells were plated at a density of 5000 cells per well and then treated with 2‰ (v/v) DMSO 
(Control) or with different doses of Silibinin (12.5, 25, 50, 100, 200, 400 and 800 μM) for 
24, 48 and 72 h. Cell viability was then determined by a MTT assay. Significance was 
determined by a Student’s t-test (p < 0.05, compared with control). 
 
    
2.2. Effect of Silibinin on the Induction of Apoptosis 
The growth inhibitory effects of Silibinin were evaluated to determine if they correlated with the 
induction of apoptosis. Cancer develops when the balance between cell proliferation and cell death is 
disturbed, and the aberrant cell proliferation leads to tumor growth. It is well known that apoptosis and 
its related signaling pathways have a profound effect on the progression of cancer [12], suggesting that 
agents inducing apoptotic death of human cancer cells, including pancreatic cancer, may play a critical 
role  in  cancer  prevention/intervention.  Morphological  analysis  using  DAPI  staining  revealed  the 
presence of nuclei with chromatin condensation and the formation of apoptotic bodies in cells cultured 
with Silibinin. In this study, no differences were found between 2‰ (v/v) DMSO and negative control 
(Figure 2A). In addition, flow cytometric analyses revealed enhanced apoptosis of AsPC-1, Panc-1 and 
BxPC-3 cells treated with Silibinin in a concentration dependent manner (Figure 2B and 2C), based on 
the formation of a significant accumulation of early apoptosis (Annexin V-positive and PI-negative) 
cells. In AsPC-1 cells, after 100 μM Silibinin treatment for 24, 48, and 72 h, percentages of apoptotic 
cells were 13.24%, 25.02%, and 29.03%. In BxPC-3, after 100 μM Silibinin treatment for 24, 48, and 
(A) 
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72  h,  percentages  of  apoptotic  cells  were  7.02%,  18.14%,  and  23.03%.  In  Panc-1,  after  100  μM 
Silibinin  treatment  for  24,  48,  and  72  h,  percentages of  apoptotic  cells  were  6.03%,  15.09%,  and 
20.34%. These results revealed enhanced apoptosis of AsPC-1, Panc-1 and BxPC-3 cells treated with 
Silibinin  in  a  time  dependent  manner.  All  these  findings  demonstrated  that  the  inhibition  effects 
observed in response to Silibinin were mainly associated with the induction of apoptotic cell death in 
AsPC-1, Panc-1 and BxPC-3 cells. However, AsPC-1 was the most sensitive cell line to Silibinin. 
Several classes of chemotherapy drugs cause apoptotic death of cancer cells, but their non-selective 
efficacy  (toxicity)  in  other tissues  has  been  a  limitation  in  their  efficacy.  Our  data  demonstrating 
significant apoptotic death  induction by Silibinin in  AsPC-1 cells, but only slightly  in Panc-1 and 
BxPC-3 cells, suggested the possibility of both selectivity and specificity in Silibinin efficacy against 
pancreatic AsPC-1 cells. 
Figure 2. Silibinin induced cell apoptosis in AsPC-1, Panc-1 and BxPC-3 cells. (A) Cells 
were treated with 2‰ (v/v) DMSO (Control) and 200 μM Silibinin for 24 h. Cells were 
then  fixed  and  stained  with  DAPI.  Stained  nuclei  were  observed  under  a  fluorescent 
microscope using a blue filter; (B) Cells treated with 100, 200 μM of Silibinin for 48 h 
were assessed for apoptosis by staining with Annexin V-FITC and PI; (C) Cells treated 
with  100,  200  μM  of  Silibinin  for  48  h  were  assessed  for  apoptosis  by  staining  with 
Annexin V-FITC and PI. The results are shown from one of three experiments with similar 
results.  Each  point  represents  the  mean  ±  SD  of  three  independent  experiments. 
Significance was determined using a Student’s t-test (p < 0.05, compared with control). 
 
(A) 
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2.3. Silibinin Triggers Apoptosis by Activating the Caspases  
It  is  well  known  that  chemotherapeutic  agents  induce  apoptosis  in  most  cells  via  two  major 
pathways:  death  receptor-mediated  pathway  and  mitochondria-mediated  pathway  [13,14].  Both 
pathways converge to a final common pathway  involving the activation of a cascade of proteases 
called caspases, which can cleave regulatory and structural molecules, and thus induce cell death [15]. 
Silibinin  induced  cell  apoptosis  both  in  a  manner  dependent  on  caspases  activation  [8,16]  or 
independent of caspases activation [9] in human carcinoma cells. 
We first investigated the effect of Silibinin on caspase-3 (an effector caspase). The results show the 
caspases involvement in Silibinin-triggered apoptosis in AsPC-1, Panc-1 and BxPC-3 cells. Silibinin 
significantly cleaved pro-caspase-3 and activated the caspase-3. The effect of Silibinin on caspase-8 
and  caspase-9  were  then  evaluated,  and  Silibinin  cleaved  pro-caspase-8  and  pro-caspase-9  and 
activated both caspase-8 and caspase-9 (Figure 3). All these findings implicated both the mitochondrial 
pathway  and  the  death  receptor  pathway  in  Silibinin-driven  apoptosis  in  AsPC-1,  Panc-1,  and  
BxPC-3 cells. 
Figure 3. Silibinin triggers apoptosis by activating caspases. (A–C) Cells were incubated 
with 100 or 200 μM Silibinin for 48 h. Equal amounts of cell lysates were assayed for 
caspase-3,  caspase-8  and  caspase-9  activity  using  DEVD-pNA,  IETD-pNA  and  
LEHD-pNA  as  substrates,  respectively.  The  concentrations  of  the  fluorescent  products 
released were then measured; (D) Cells were incubated with 0, 100, 200 μM of Silibinin 
for 24 h. Equal amounts of cell lysates were then resolved by SDS-PAGE, transferred to 
PVDF membrane, and probed with anti-caspase 3, 8, or 9 antibodies. The proteins were 
then visualized using a detection system. β-actin was used as an internal control. Results 
represent the mean ± SD of triplicate determinations. The significance was determined by a 
Student’s t-test (p < 0.05, compared with control).  
   
(A)  (B) 
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2.4. Silibinin Induces Cell-Cycle Arrest in Human AsPC-1, but not in Panc-1 and BxPC-3 Cells 
To gain an insight into the mechanism of the anti-proliferative activity of Silibinin, its effects on 
cell cycle distribution were determined. In general, the progression of cell cycle in eukaryotes is a 
complex process involving resting G0 phase, and cell growth involving G1, S and G2/M phases in a 
step-wise manner [17]. Silibinin caused cell cycle arrest in different phases in different cancer cells. 
For example, Silibinin caused G1 and G2/M cell cycle arrest via distinct circuitries in human prostate 
cancer  PC3  cells  [18].  Silibinin  inhibits  human  nonsmall  cell  lung  cancer  cell  growth  through  
cell-cycle arrest in G1 phase by modulating expression and function of key cell-cycle regulators [19]. 
Silibinin promotes cell-cycle arrest in G2/M phase in Fet and Geo cell lines and G1 arrest in HCT116 
of human colon cancer [17]. In this text, our findings showing that Silibinin induced G1 arrested in 
AsPC-1  cells  versus  no  obvious  G1,  S  or  G2  arrest  in  BxPC-3  and  Panc-1  cells  under  identical 
treatment conditions, further showed some selectivity and specificity  in  its  biological responses  in 
different pancreatic cancer cell types. It was also important to identify here that Silibinin showed better 
efficacy in AsPC-1 cells versus BxPC-3 and Panc-1 cells following treatments at different doses. All 
these findings implicated that Silibinin inhibited different pancreatic cancer cells in a different manner. 
More studies, however, are needed in the future to find the mechanism of Silibinin action. The data 
presented in this study also supported and warranted Silibinin efficacy studies in pre-clinical pancreatic 
AsPC-1 models.  
Figure 4. Silibinin triggers cell cycle arrest. (A) The DNA content of cells treated with 
Silibinin for the indicated times was analyzed by flow cytometry. Cell-cycle distributions 
after  treatment  with  100,  200  μM  Silibinin  for  24  h.  DMSO  as  the  negative  control.  
Cell-cycle distributions were assessed by PI staining. The DNA content of 15,000 events was 
analyzed by flow cytometry; (B) The number of G1, S and G2 phase cells from Figure 4A. 
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Figure 4. Cont. 
 
3. Experimental Section  
3.1. Cell Line and Reagents 
Human pancreatic cancer cells, AsPC-1, Panc-1 and BxPc-3, were purchased  from the Chinese 
Academy of Sciences Cell Bank. Cells were cultured in DMEM medium containing 10% fetal bovine 
serum (Gibico, NY, USA) and 1% penicillin-streptomycin under standard culture conditions (37 °C, in 
95% humidified air containing 5% CO2). Silibinin was obtained from Sigma and dissolved in DMSO 
at concentration of 500 mM. 
Annexin-V-FITC  Apoptosis  Detection  Kit  I  was  obtained  from  BD,  PVDF  membrane  was 
purchased  from  Millipore,  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide  (MTT),  
4,6-diamidino-2-phenylindile  (DAPI),  propidium  iodide  (PI)  were  purchased  from  Sigma,  Caspase 
activity assay kits were obtained from Bestbio., DMEM was purchased from Invitrogen Corp. and  
fetal  bovine  serum  (FBS)  was  purchased  from  GIBCO–BRL.  Antibodies  against  Pro-caspase-3,  
Pro-caspase-8, Pro-caspase-9 and HRP-labeled goat anti-mouse IgG were purchased from Santa Cruz 
Biotechnology;  Antibody  against  β-actin  was  obtained  from  Sigma.  All  other  chemicals  not 
specifically cited here were purchased from Sigma (St. Louis, MO, USA). 
3.2. Cell Proliferation Assay 
To  compare  the  sensitivities  of  different  pancreatic  cancer  cells  to  Silibinin  treatment,  MTT 
proliferation assays were performed to determine cell viability [19]. Cells (5 × 10
3) were seeded in  
96-well plates, and after 24 h, fed with fresh medium or different doses Silibinin (12.5, 25, 50, 100, 
200, 400, and 800 μM) in complete medium. After 24, 48, and 72 h of treatment, 20 μL MTT reagent 
(5 mg/mL,  Sigma) was added to each well  for 4 h incubation  in a CO2 incubator. Thereafter, the 
medium containing MTT was removed and 150 μL dimethylsulfoxide (DMSO) was loaded into each 
well to dissolve Formazan crystals. Metabolically active cells were spectrophotometrically quantified 
at 490 nm by detection of reduced yellow tetrazolium MTT to an intracellular purple formazan. The 
process was repeated in triplicate for all treatment concentrations to confirm accuracy. 
(B) Int. J. Mol. Sci. 2011, 12 
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3.3. Nuclear Staining with DAPI 
After treated with the inhibitor Silibinin, the cells in a 24-well plate were washed with ice-cold 
phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol for 5 min at 4 °C. The fixed  
cells were then washed with PBS, and stained with 300 μL of DAPI (2.5 μg/mL) solution for 5 min  
at  room  temperature  in  the  dark.  The  nuclear  morphology  of  the  cells  was  then  examined  by  a 
fluorescent microscope.  
3.4. Flow Cytometric Analysis: Cell Cycle and Apoptosis 
Cell  cycle  arrest  and  apoptosis  were  studied  by  flow  cytometry  as  described  [20,21].  AsPC-1,  
Panc-1 and BxPc-3 cells were plated in 6-well plate under standard culture conditions. After 24 h, cells 
were fed with fresh medium and treated with DMSO alone or different doses of Silibinin (μM). After 
24, 48, and 72 h of treatment, medium was aspirated, cells were quickly washed twice with ice-cold 
PBS and trypsinized, and cell pellets were collected. For cell cycle analysis studies, cells were fixed in 
ice-cold 70% ethanol and then stored at 4 °C overnight. Prior to analysis, the cells were washed twice 
with PBS, suspended in 0.5 mL of cold PI solution containing 10 μL RNase A (25 μg/mL), 10 μL PI 
(50 μg/mL), and then incubated at 37 °C for an additional 30 min in the dark. For apoptosis analysis, 
cells (10
6) were washed with PBS (0.01 M, pH 7.4) and then resuspended in binding buffer according 
to the manufacturer’s protocols. Aliquots of the cells were then incubated with Annexin-V- FITC and 
PI, mixed, and incubated for 15 min at room temperature in the dark. Next, cell cycle distribution and 
induction of apoptosis were determined by analyzing 15,000 ungated cells using a FACScan cytometer 
and Cell Quest software (FACSCalibur; Becton-Dickinson, San Jose, CA, USA). All experiments were 
performed in triplicate. 
3.5. Caspase Activity Assay 
Caspase activities were determined by colorimetric assays using caspase-3, caspase-8 and caspase-9 
activation kits according to the manufacturer’s protocols. Briefly, at the end of treatment with Silibinin 
for 24 h, the cells were washed twice with PBS (0.01 M, pH 7.4) and scraped with a rubber policeman. 
Cells were centrifuged at 10,000× g at 4 °C, and the cell pellet was lysed in 100 μL of the supplied 
lysis  buffer. The resulting suspension was centrifuged at 10,000× g, 4 °C, 10 min,  and 10–20 μL 
supernatant was used for caspase assay. The supernatants were then collected and incubated at 37 °C, 
with the supplied reaction buffer, which contained dithiothreitol and substrates. The caspase activity 
was then determined by measuring changes in the absorbance at 405 nm using a microplate reader. 
3.6. Western Blotting Analysis 
The protocol for Western blotting has been described earlier [22]. Cells were treated with Silibinin 
and  washed  twice  with  ice  cold  PBS,  and  gently  lysed  for  30  min  in  ice-cold  cell  lysis  buffer  
(50 mmol/L Tris (pH 8.0), 150 mmol/L NaCl, 0.1% SDS, 1% NP40 and 0.5% sodium deoxycholate) 
containing  proteinase  inhibitors  (1%  Cocktail  and  1  mmol/L  PMSF).  Lysates  were  centrifuged  at 
10,000× g for 10 min at 4 C. Supernatants were collected, and protein concentrations were determined 
using Bradford assay.  For Western blotting analysis, an equal amount of protein was subjected to Int. J. Mol. Sci. 2011, 12 
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electrophoresis  on  an  SDS-polyacrylamide  gel  and  transferred  to  a  PVDF  membrane  by  electro 
blotting. The blots were blocked in Tris buffer saline (TBS) containing 5% non-fat milk and 0.1% 
Tween-20 (blotting grade) for 1 h, and then probed with the desired antibodies overnight at 4 C. 
Membranes  were  subsequently  incubated  with  appropriate  horseradish  peroxidase-conjugated 
secondary antibody for 2 h, and visualized by Western blotting detection reagents containing PCA  
and luminol. 
3.7. Statistical Analysis 
Statistical  analysis  was  performed  with  statistical  program  for  social  sciences  software  (SPSS, 
Chicago, IL, USA) as needed. All data were expressed as mean ± SEM and a statistically significant 
difference was considered to be present at p < 0.05. Unless mentioned otherwise, all the assays were 
repeated in triplicate in three independent experiments. 
4. Conclusions 
Silibinin  treatment  of  AsPC-1,  BxPC-3  and  Panc-1  cells  resulted  in  a  significant  dose-  and  
time-dependent growth inhibition and apoptosis. Silibinin activated caspase 3/8/9 causing apoptotic 
death of human pancreatic cells and induced a decrease in S phase and cell cycle arrest in G1 phase in 
AsPC-1  cells,  but  resulted  in  no  changes  in  BxPC-3  and  Panc-1  cells.  Silibinin  showed  some 
selectivity and specificity  in biological responses in different pancreatic cancer cell types and better 
efficacy in AsPC-1 cells versus BxPC-3 and Panc-1 cells. Therefore, Silibinin may circumvent the 
resistance mechanisms that limit the success of conventional drugs, providing a strong rationale for 
future studies evaluating preventive and/or intervention strategies for Silibinin in pancreatic cancer 
pre-clinical models. 
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